Aspire Biopharma Holdings (ASBP) Assets Average (2022 - 2026)
Aspire Biopharma Holdings (ASBP) posted quarterly Assets Average of $4.2 million for Q1 2026, up 298.83% year-over-year from $1.1 million in Q1 2025, and up 126.88% quarter-over-quarter from $1.9 million in Q4 2025.
Aspire Biopharma Holdings (ASBP) Assets Average (2022 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Assets Average for 5 consecutive years, with $4.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 298.83% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $4.2 million (up 298.83% YoY), while the FY2025 annual figure was $730077.5, down 92.75% from the prior year.
- Assets Average climbed to $4.2 million in Q1 2026 per ASBP's latest filing, from $1.9 million in the prior quarter.
- Across five years, Assets Average topped out at $301.6 million in Q1 2023 and bottomed at $1.1 million in Q1 2025.
- Historically, Assets Average has averaged $105.9 million across 5 years, with a median of $20.1 million in 2024.
- Annual changes were most pronounced in 2025 — Assets Average sank 94.74% — and 2026, when it surged 298.83%.
- Aspire Biopharma Holdings' Assets Average stood at $299.0 million in 2022, then sank by 93.33% to $19.9 million in 2023, then plunged by 32.12% to $13.5 million in 2024, then plunged by 86.27% to $1.9 million in 2025, then surged by 126.88% to $4.2 million in 2026.
- Business Quant data shows ASBP's Assets Average at $4.2 million in Q1 2026, $1.9 million in Q4 2025, and $1.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.25 Bn | 131.40 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.04 Bn | 78.05 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.43 Bn | 60.25 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.26 Bn | 53.13 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.31 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.03 Bn | 9.63 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.49 Bn | 26.33 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 19.82 Bn |
| 10 | Aspire Biopharma Holdings | 8.26 Mn | -3.91 Mn | -30,086.00 | 10.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 10.33 Mn |
| Mar 31, 2026 | 4.21 Mn |
| Dec 31, 2025 | 1.86 Mn |
| Sep 30, 2025 | 1.70 Mn |
| Jun 30, 2025 | 1.48 Mn |
| Mar 31, 2025 | 1.06 Mn |
| Jun 30, 2024 | 13.53 Mn |
| Mar 31, 2024 | 20.09 Mn |
| Dec 31, 2023 | 19.94 Mn |
| Sep 30, 2023 | 20.23 Mn |
| Jun 30, 2023 | 161.84 Mn |
| Mar 31, 2023 | 301.64 Mn |
| Dec 31, 2022 | 299.01 Mn |
| Sep 30, 2022 | 297.28 Mn |
| Jun 30, 2022 | 296.61 Mn |
| Mar 31, 2022 | 148.40 Mn |